68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT to guide the surgical treatment of medullary thyroid carcinoma (MTC). The surgical extent of MTC is determined based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, with the main endpoint being 1-month post-surgical calcitonin level.
- EligibilityCriteria: Inclusion Criteria:  Age between 18 and 75 years； Diagnosed with MTC and have surgical indication based on preliminary evaluation; the tumor may be newly diagnosed or previously treated; Expected survival of at least 12 weeks; No major organ dysfunction (heart, lung, liver, kidney and other major organ include), acute or life-threatening status of infection; Be willing and able to understand the research content and provide written informed consent/assent for the trial.  Exclusion Criteria:  Have a history of imaging agent allergies; Does not meet the PET-CT scan sedation requirements, or has contraindications for PET-CT examination; Be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial; No surgical indication (i.e., no measurable disease, unresectable disease, or significant present of distant metastasis), refusing surgery or 68Ga-TCR-FAPI PET/CT-guided surgery. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult